These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 24132686)
1. Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery. Ekins S; Freundlich JS; Hobrath JV; Lucile White E; Reynolds RC Pharm Res; 2014 Feb; 31(2):414-35. PubMed ID: 24132686 [TBL] [Abstract][Full Text] [Related]
2. Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models. Ekins S; Reynolds RC; Franzblau SG; Wan B; Freundlich JS; Bunin BA PLoS One; 2013; 8(5):e63240. PubMed ID: 23667592 [TBL] [Abstract][Full Text] [Related]
3. Fusing dual-event data sets for Mycobacterium tuberculosis machine learning models and their evaluation. Ekins S; Freundlich JS; Reynolds RC J Chem Inf Model; 2013 Nov; 53(11):3054-63. PubMed ID: 24144044 [TBL] [Abstract][Full Text] [Related]
4. Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis. Ekins S; Kaneko T; Lipinski CA; Bradford J; Dole K; Spektor A; Gregory K; Blondeau D; Ernst S; Yang J; Goncharoff N; Hohman MM; Bunin BA Mol Biosyst; 2010 Nov; 6(11):2316-2324. PubMed ID: 20835433 [TBL] [Abstract][Full Text] [Related]
5. Validating new tuberculosis computational models with public whole cell screening aerobic activity datasets. Ekins S; Freundlich JS Pharm Res; 2011 Aug; 28(8):1859-69. PubMed ID: 21547522 [TBL] [Abstract][Full Text] [Related]
6. Machine Learning Model Analysis and Data Visualization with Small Molecules Tested in a Mouse Model of Mycobacterium tuberculosis Infection (2014-2015). Ekins S; Perryman AL; Clark AM; Reynolds RC; Freundlich JS J Chem Inf Model; 2016 Jul; 56(7):1332-43. PubMed ID: 27335215 [TBL] [Abstract][Full Text] [Related]
7. Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Models for Mycobacterium tuberculosis Drug Discovery. Ekins S; Madrid PB; Sarker M; Li SG; Mittal N; Kumar P; Wang X; Stratton TP; Zimmerman M; Talcott C; Bourbon P; Travers M; Yadav M; Freundlich JS PLoS One; 2015; 10(10):e0141076. PubMed ID: 26517557 [TBL] [Abstract][Full Text] [Related]
8. Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery. Lane T; Russo DP; Zorn KM; Clark AM; Korotcov A; Tkachenko V; Reynolds RC; Perryman AL; Freundlich JS; Ekins S Mol Pharm; 2018 Oct; 15(10):4346-4360. PubMed ID: 29672063 [TBL] [Abstract][Full Text] [Related]
11. Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis. Ekins S; Casey AC; Roberts D; Parish T; Bunin BA Tuberculosis (Edinb); 2014 Mar; 94(2):162-9. PubMed ID: 24440548 [TBL] [Abstract][Full Text] [Related]
12. Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis. Sarker M; Talcott C; Madrid P; Chopra S; Bunin BA; Lamichhane G; Freundlich JS; Ekins S Pharm Res; 2012 Aug; 29(8):2115-27. PubMed ID: 22477069 [TBL] [Abstract][Full Text] [Related]
13. Are bigger data sets better for machine learning? Fusing single-point and dual-event dose response data for Mycobacterium tuberculosis. Ekins S; Freundlich JS; Reynolds RC J Chem Inf Model; 2014 Jul; 54(7):2157-65. PubMed ID: 24968215 [TBL] [Abstract][Full Text] [Related]
14. Target Discovery for New Antitubercular Drugs Using a Large Dataset of Growth Inhibitors from PubChem. Goldman RC Infect Disord Drug Targets; 2020; 20(3):352-366. PubMed ID: 30520384 [TBL] [Abstract][Full Text] [Related]